Recent Updates
Recently added Catalysts

PF-02413873

Phase 1

Endometriosis | Small molecule | Endocrine |Pfizer, Inc.|Last Updated: Feb 10, 2010

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment42

FDA Designations

No designations recorded

Clinical trial landscape

PF-02413873 · 1 trial · 1 indication

Phase 1 1
NCT00800618A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young WomenEndometriosis
COMPLETED42 Analytics
PHASE1COMPLETED
A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women
Endometriosis
NCT0080061842
Unlock trial analytics

Study Endpoints

Primary Endpoints

Adverse events, vital signs measurements, 12-lead ECGs, physical examination findings, blood safety tests.
1 month
PF-02413873 pharmacokinetics
1 month
Endometrial thickness, Ovarian follicular estradiol secretion, Pre-ovulatory LH surge, Corpus Luteum progesterone secretion.
14 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
PF-02413873EXPERIMENTALPF-2413873 active treatment
PlaceboPLACEBO_COMPARATORPlacebo

Interventions

NameTypeDescription
PF-02413873 100 mg QDDRUG100 mg of PF-02413873 oral suspension once daily for 14 days
PF-02413873 1500 mg QDDRUG1500 mg of PF-02413873 oral suspension once daily for 14 days
PF-02413873 20 mg QDDRUG20 mg of PF-02413873 oral suspension once daily for 14 days
PF-02413873 500 mg QDDRUG500 mg of PF-02413873 oral suspension once daily for 14 days
PF-02413873 PlaceboDRUGPF-0241383 Placebo once daily for 14 days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 35 Years
SexFEMALE
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: * Healthy women of childbearing potential with a regular menstrual cycle Exclusion Criteria: * Evidence or history of any major disease * Pregnant or nursing women * Requirement for chronic medication

Countries:United StatesBelgium
Unlock Eligibility Criteria

Frequently asked questions about PF-02413873

What is PF-02413873 used for?

PF-02413873 is an investigational small molecule being developed for endometriosis. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied for its effects on sex hormone levels in healthy young women.

Who makes PF-02413873?

PF-02413873 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics.

What phase is PF-02413873 in?

PF-02413873 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 trial has been completed, with results expected to inform further development.

What clinical trials is PF-02413873 in?

PF-02413873 has one completed Phase 1 trial, NCT00800618, which enrolled 42 healthy young women in the United States and Belgium. The study investigated how the body handles multiple doses of the drug and its effect on sex hormone levels.

Is PF-02413873 the same as PF-0243873?

PF-02413873 is the drug name, while PF-0243873 appears in the clinical trial title as a possible alternative name. The study NCT00800618 refers to both names, suggesting they may refer to the same compound.